Healthcare [ 7/13 ] | Biotechnology [ 82/163 ]
NASDAQ | Common Stock
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer.
The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.
It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types.
The company was founded in 2007 and is headquartered in San Diego, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 14, 24 | -0.48 Increased by +17.24% | -0.54 Increased by +11.11% |
| Mar 26, 24 | -0.56 Increased by +11.02% | -0.79 Increased by +29.04% |
| Nov 7, 23 | -0.70 Decreased by -1.45% | -0.80 Increased by +12.50% |
| Aug 1, 23 | -0.75 Increased by +2.60% | -0.64 Decreased by -17.19% |
| May 11, 23 | -0.58 Increased by +10.77% | -0.63 Increased by +7.94% |
| Mar 23, 23 | -0.63 Decreased by -1.61% | -0.70 Increased by +10.00% |
| Nov 3, 22 | -0.69 Decreased by -1.47% | -0.80 Increased by +13.75% |
| Aug 9, 22 | -0.77 Increased by +14.44% | -0.69 Decreased by -11.59% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 0.00 Decreased by N/A% | -23.23 M Increased by +10.60% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 1.71 M Increased by +N/A% | -26.93 M Increased by +3.01% | Decreased by -1.58 K% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -33.33 M Decreased by -31.15% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -35.75 M Decreased by -24.31% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -25.99 M Decreased by -7.57% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by -100.00% | -27.76 M Decreased by -18.69% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by -100.00% | -25.41 M Decreased by -10.81% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by -100.00% | -28.76 M Increased by +5.34% | Decreased by N/A% Decreased by N/A% |